Our unique platform technology seeks to harness and promote the body’s immune system against cancerous tumours. Our product pipeline includes oncolytic viruses and immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies.